HTFL vs WGS
HTFL: HeartFlow uses AI-powered software to transform standard cardiac scans into actionable 3D insights for non-invasive coronary artery disease diagnosis and treatment planning. WGS: GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support precision medicine across clinical and research settings.
Side-by-side fundamentals
| Metric | HTFL | WGS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.23 | $62.60 | |
| Market cap as of 2026-07-23 | $2.2B | $1.9B | |
| PEG as of 2026-07-23 | n/a | -0.30 | |
| Net margin as of 2026-07-23 | -58.4% | -17.6% | WGS higher |
| Gross margin as of 2026-07-23 | +78.1% | +69.6% | HTFL higher |
| Operating margin as of 2026-07-23 | -43.1% | -16.4% | WGS higher |
| ROE as of 2026-07-23 | -38.9% | -27.5% | WGS higher |
| ROA as of 2026-07-23 | -36.4% | -15.7% | WGS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.38 | HTFL lower |
| Revenue growth (YoY) as of 2026-07-23 | +41.3% | +34.1% | HTFL higher |
| Revenue CAGR (3y) SEC XBRL | +42.1% | +22.1% | HTFL higher |
| Beta as of 2026-07-23 | 1.99 | 2.01 | |
| 1-year return as of 2026-07-22 close | -12.7% | -21.3% | HTFL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.